| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Special Contributions |
1 Department of Molecular and Medical Pharmacology and Ahmanson Biological Imaging Center, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California
2 Department of Biomathematics and Crump Institute for Molecular Imaging, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California
3 Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California
4 Department of Internal Medicine and Center on Aging, UCLA School of Medicine, University of California, Los Angeles, Los Angeles, California
Evaluating dementia in patients with early symptoms of cognitive decline is clinically challenging. Growing evidence indicates that appropriate incorporation of PET into the clinical work-up can improve diagnostic and prognostic accuracy with respect to Alzheimer’s disease (AD), the most common cause of dementia in the geriatric population. The precise diagnostic role of PET and its economic impact in this context, however, have not been systematically examined previously. Methods: We compared the relative value of 2 strategies for assessing whether early AD is responsible for cognitive symptoms in geriatric patients: (a) a conventional approach, based largely on establishing clinical criteria for the presence of dementia and excluding non-AD etiologies that could contribute to the patient’s symptoms, and (b) a proposed approach using PET to examine regional cerebral metabolism and look for characteristic patterns of abnormal metabolism. The total costs (measured in dollars) and benefits (measured in number of accurate diagnoses) of diagnostic testing and clinical outcomes accruing to each strategy were calculated using formalized tools of decision analysis. The primary outcome measure by which the strategies were compared was the ratio of costs to benefits obtained following each approach. Results: Following the proposed approach led to improved accuracy in identifying early AD, without adding to the overall costs of diagnosis and treatment ($3,433 vs. $3,564 per patient approached by the proposed or conventional algorithm, respectively). The strategy making use of PET was associated with a reduced rate of false-negative and false-positive findings compared with the conventional approach (3.1% vs. 8.2% and 12.0% vs. 23.0%, respectively, at a prevalence of 51.6% in the studied symptomatic population) and a cost savings of $1,138 per correct diagnosis rendered ($4,047 vs. $5,185). The lower cost per unit benefit for the proposed strategy was maintained over a wide range of tested values for variables of sensitivity, specificity, costs of PET and long-term care, and varying approaches to the use of structural neuroimaging. Conclusion: Appropriate use of PET for evaluating early dementia in geriatric patients can add valuable information to the clinical work-up, without adding to the overall costs of evaluation and management, resulting in a greater number of patients being accurately diagnosed for the same level of financial expenditure. Thus, the opportunity exists for diminishing the morbidity of dementia economically, with earlier institution of more appropriate management in evaluated patients.
Key Words: Alzheimer’s disease • dementia • PET • FDG • functional brain imaging • cost-to-benefit ratio • cost-effectiveness • decision tree • decision analysis
This article has been cited by other articles:
|
|
 |
|
  B. Kuczynski, W. Jagust, H. C. Chui, and B. Reed An inverse association of cardiovascular risk and frontal lobe glucose metabolism Neurology, February 24, 2009; 72(8): 738 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Jalbert, L. A. Daiello, and K. L. Lapane Dementia of the Alzheimer Type Epidemiol. Rev., November 1, 2008; 30(1): 15 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mosconi, W. H. Tsui, K. Herholz, A. Pupi, A. Drzezga, G. Lucignani, E. M. Reiman, V. Holthoff, E. Kalbe, S. Sorbi, et al. Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias J. Nucl. Med., March 1, 2008; 49(3): 390 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S L PIMLOTT and K P EBMEIER SPECT imaging in dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S153 - S159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Matsuda Role of Neuroimaging in Alzheimer's Disease, with Emphasis on Brain Perfusion SPECT J. Nucl. Med., August 1, 2007; 48(8): 1289 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. W. Bokde, P. Lopez-Bayo, T. Meindl, S. Pechler, C. Born, F. Faltraco, S. J. Teipel, H.-J. Moller, and H. Hampel Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment Brain, May 1, 2006; 129(5): 1113 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Marseille and D. H.S. Silverman Recognition and treatment of Alzheimer's disease: A case-based review American Journal of Alzheimer's Disease and Other Dementias, March 1, 2006; 21(2): 119 - 125. [Abstract] [PDF]
|
|
|
|
|
|
E. T. Wimberley, A. Herrera, B. Kidrowski, D. Brown, and L. L'Esperance A cognitive and physical performance assessment of retirees entering a continuing care retirement community: The Moorings Assessment Protocol American Journal of Alzheimer's Disease and Other Dementias, March 1, 2003; 18(2): 73 - 78. [Abstract] [PDF]
|
|
|
|
 |
|
 D. H.S. Silverman and G. W. Small Prompt Identification of Alzheimer's Disease With Brain PET Imaging of a Woman With Multiple Previous Diagnoses of Other Neuropsychiatric Conditions Am J Psychiatry, September 1, 2002; 159(9): 1482 - 1488. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
